• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Director Henry Scott Robert sold $7,825 worth of shares (3,000 units at $2.61), decreasing direct ownership by 2% to 135,053 units (SEC Form 4)

    4/14/25 5:00:18 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care
    Get the next $NXGL alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    X
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Henry Scott Robert

    (Last) (First) (Middle)
    C/O NEXGEL, INC.
    2150 CABOT BLVD, WEST, SUITE B

    (Street)
    LANGHORNE PA 19047

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    NEXGEL, INC. [ NXGL ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    04/10/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 04/10/2025 S 3,000(1) D $2.6083(2) 135,053 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The Reporting Person sold these shares pursuant to a Rule 10b5-1 trading plan. The shares were originally purchased by the Reporting Person in the open market on September 16, 2022 and were not purchased in the recent registered direct offerings of the Issuer.
    2. Represents the weighted average of open market sale transactions ranging from $2.5001 to $2.6750 per share. The Reporting Person undertakes to provide full information regarding the number of shares sold at each separate price sold if requested by the Securities and Exchange Commission Staff, the Issuer or a security holder of the Issuer.
    /s/ Scott Robert Henry 04/14/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $NXGL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NXGL

    DatePrice TargetRatingAnalyst
    2/25/2022$6.00Buy
    Maxim Group
    More analyst ratings

    $NXGL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NEXGEL to Report First Quarter 2025 Financial Results on May 13th

      Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the first quarter 2025, after the market close on May 13, 2025. Following the release of its financial results, the Company will host a conference call at 4:30 p.m. ET on the same day. First Quarter 2025 Financial Results Conference CallDate: May 13, 2025Time: 4:30 P.M. ETLive Call: 1-800-343-4849 (U.S. Toll Free) or 1-203-518-9848 (Internatio

      5/9/25 9:00:00 AM ET
      $NXGL
      Medical/Dental Instruments
      Health Care
    • NEXGEL to Present at the Planet MicroCap Showcase in Las Vegas, NV April 22nd-24th

      LANGHORNE, Pa., April 07, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer, will be presenting at the Planet MicroCap Showcase: Vegas 2025, taking place at the Paris Hotel & Casino, Las Vegas, NV on April 22-24, 2025. Planet MicroCap Showcase: Vegas 2025Presentation Date: Wednesday, April 23, 2025Presentation Time: 9:30 a.m. PT Location: Paris Hotel & Casino, Las Vegas, NV, in Track 4 - LoireWebcast: https://ir.nexgel.com/news-events/events-

      4/7/25 9:00:00 AM ET
      $NXGL
      Medical/Dental Instruments
      Health Care
    • NEXGEL Reports Record Fourth Quarter and Full Year 2024 Financial Results

      Fourth quarter 2024 revenue totaled $3.04 million, an increase of 181%, as compared to $1.08 million for the same period the prior year Full year 2024 revenue totaled $8.69 million, an increase of 112%, as compared to $4.09 million in 2023 Over 100% full year and fourth quarter revenue growth year-over-year for third consecutive year Company issues revenue guidance of $13 million for 2025 and expects to achieve positive EBITDA during the year LANGHORNE, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced record

      3/24/25 4:05:00 PM ET
      $NXGL
      Medical/Dental Instruments
      Health Care

    $NXGL
    Leadership Updates

    Live Leadership Updates

    See more
    • NEXGEL Appoints Joseph F. McGuire as Chief Financial Officer

      LANGHORNE, Pa., Jan. 02, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the appointment of Joseph F. McGuire as Chief Financial Officer, effective January 1, 2025. Adam E. Drapczuk III, current Chief Financial Officer, will remain with the Company as a consultant. Adam Levy, Chief Executive Officer, stated, "As our business continues to experience high growth, it is imperative we consistently acquire talented and experienced professionals to join our team particularly in operati

      1/2/25 9:00:00 AM ET
      $NXGL
      Medical/Dental Instruments
      Health Care
    • NEXGEL Appoints Kip Crecca to its Scientific Advisory Board

      LANGHORNE, Pa., Oct. 04, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the appointment of Kip Crecca to its Scientific Advisory Board. "We are thrilled to appoint Kip to our Scientific Advisory Board. He adds to our team a wealth of knowledge and experience as a top medical device sales professional," said Adam Levy, NEXGEL's CEO. "Mr. Crecca will be invaluable to the Company as we advance our medical device and healthcare programs. He is an important addition to our group of e

      10/4/24 9:00:00 AM ET
      $NXGL
      Medical/Dental Instruments
      Health Care
    • NEXGEL Appoints Scott Henry, CFA to Board of Directors and Audit Committee

      LANGHORNE, Pa., Jan. 17, 2023 /PRNewswire/ -- NEXGEL, Inc. (NASDAQ:NXGL, NXGLW))), ("NEXGEL" or the "Company"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, announced today the appointment of Scott Henry, CFA as a new independent director to the Company's Board of Directors (the "Board"), effective immediately. Mr. Henry will also serve as a member of the Board's Audit Committee. "Scott brings a wealth of financial and operational experience to NEXGEL, making him an ideal addition to our Board and Audit Committee," said Adam Levy, Chief Executive Officer of NEXGEL. "Additionally, his vast network within the investment comm

      1/17/23 7:30:00 AM ET
      $NXGL
      Medical/Dental Instruments
      Health Care

    $NXGL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Levy Adam R. bought $9,999 worth of shares (3,636 units at $2.75), increasing direct ownership by 1% to 333,196 units (SEC Form 4)

      4 - NEXGEL, INC. (0001468929) (Issuer)

      11/22/24 4:54:14 PM ET
      $NXGL
      Medical/Dental Instruments
      Health Care
    • Director Zeldis Jerome B bought $9,999 worth of shares (3,636 units at $2.75), increasing direct ownership by 4% to 106,664 units (SEC Form 4)

      4 - NEXGEL, INC. (0001468929) (Issuer)

      11/22/24 4:54:12 PM ET
      $NXGL
      Medical/Dental Instruments
      Health Care
    • Director Stein John Nachum gifted 4,000 shares and bought $9,999 worth of shares (3,636 units at $2.75), decreasing direct ownership by 0.08% to 471,456 units (SEC Form 4)

      4 - NEXGEL, INC. (0001468929) (Issuer)

      11/22/24 4:54:08 PM ET
      $NXGL
      Medical/Dental Instruments
      Health Care

    $NXGL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Henry Scott Robert sold $7,825 worth of shares (3,000 units at $2.61), decreasing direct ownership by 2% to 135,053 units (SEC Form 4)

      4 - NEXGEL, INC. (0001468929) (Issuer)

      4/14/25 5:00:18 PM ET
      $NXGL
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Levy Adam R. sold $12,038 worth of shares (4,000 units at $3.01), decreasing direct ownership by 1% to 370,284 units (SEC Form 4)

      4 - NEXGEL, INC. (0001468929) (Issuer)

      4/2/25 5:00:26 PM ET
      $NXGL
      Medical/Dental Instruments
      Health Care
    • Director Henry Scott Robert sold $8,621 worth of shares (3,000 units at $2.87), decreasing direct ownership by 2% to 138,053 units (SEC Form 4)

      4 - NEXGEL, INC. (0001468929) (Issuer)

      3/11/25 5:00:14 PM ET
      $NXGL
      Medical/Dental Instruments
      Health Care

    $NXGL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on NexGel with a new price target

      Maxim Group initiated coverage of NexGel with a rating of Buy and set a new price target of $6.00

      2/25/22 9:17:01 AM ET
      $NXGL
      Medical/Dental Instruments
      Health Care

    $NXGL
    SEC Filings

    See more
    • SEC Form DEF 14A filed by NexGel Inc

      DEF 14A - NEXGEL, INC. (0001468929) (Filer)

      4/30/25 5:01:09 PM ET
      $NXGL
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-K filed by NexGel Inc

      10-K - NEXGEL, INC. (0001468929) (Filer)

      3/27/25 4:18:30 PM ET
      $NXGL
      Medical/Dental Instruments
      Health Care
    • NexGel Inc filed SEC Form 8-K: Regulation FD Disclosure

      8-K - NEXGEL, INC. (0001468929) (Filer)

      3/25/25 9:17:15 AM ET
      $NXGL
      Medical/Dental Instruments
      Health Care

    $NXGL
    Financials

    Live finance-specific insights

    See more
    • NEXGEL to Report First Quarter 2025 Financial Results on May 13th

      Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the first quarter 2025, after the market close on May 13, 2025. Following the release of its financial results, the Company will host a conference call at 4:30 p.m. ET on the same day. First Quarter 2025 Financial Results Conference CallDate: May 13, 2025Time: 4:30 P.M. ETLive Call: 1-800-343-4849 (U.S. Toll Free) or 1-203-518-9848 (Internatio

      5/9/25 9:00:00 AM ET
      $NXGL
      Medical/Dental Instruments
      Health Care
    • NEXGEL Reports Record Fourth Quarter and Full Year 2024 Financial Results

      Fourth quarter 2024 revenue totaled $3.04 million, an increase of 181%, as compared to $1.08 million for the same period the prior year Full year 2024 revenue totaled $8.69 million, an increase of 112%, as compared to $4.09 million in 2023 Over 100% full year and fourth quarter revenue growth year-over-year for third consecutive year Company issues revenue guidance of $13 million for 2025 and expects to achieve positive EBITDA during the year LANGHORNE, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced record

      3/24/25 4:05:00 PM ET
      $NXGL
      Medical/Dental Instruments
      Health Care
    • NEXGEL to Report Fourth Quarter and Full Year 2024 Financial Results on March 24th

      Management will host a conference call at 4:30 p.m. ET on the same day LANGHORNE, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the fourth quarter and full year ended December 31, 2024, after the market closes on March 24, 2025. Following the release of its financial results, the Company will host a conference call at 4:30 P.M. ET on the same day. Fourth Quarter and Full Year 2024 Financial Results Conference CallDate: March 24, 2025Time: 4:30 p.m. ETLive Call: 1-800

      3/19/25 9:00:00 AM ET
      $NXGL
      Medical/Dental Instruments
      Health Care